Format

Send to

Choose Destination
Prim Care. 2016 Mar;43(1):61-7, viii. doi: 10.1016/j.pop.2015.08.011. Epub 2016 Jan 12.

Past, Present, and Future of Pharmacologic Therapy in Obesity.

Author information

1
Department of Family Medicine and Rural Health, The Center for Underrepresented Minorities in Academic Medicine, Florida State University College of Medicine, 1115 West Call Street, #3210 M, Tallahassee, FL 32306, USA. Electronic address: Jose.rodriguez@med.fsu.edu.
2
Department of Family Medicine and Rural Health, The Center for Underrepresented Minorities in Academic Medicine, Florida State University College of Medicine, 1115 West Call Street, #3210 N, Tallahassee, FL 32306, USA.

Abstract

Medications for obesity management can be divided into 4 groups: antidepressants (naltrexone/bupropion), stimulants (phentermine, phendimetrazine, diethylpropion, phentermine/topiramate), fat blockers (orlistat), and diabetes medications (liraglutide). Each group has specific therapeutic effects, adverse effects, and costs. Two medications are indicated for long-term use in obesity: lorcaserin and orlistat. Other available medications are for short-term use. High cost makes many of these medications inaccessible for underserved and poor patients. Because of misuse potential, many obesity medications are also classified as controlled substances. There are no medications currently approved for use in pregnant or lactating women.

KEYWORDS:

Antidepressants; Fat blockers; Obesity; Pharmacology treatment; Stimulants

PMID:
26896200
DOI:
10.1016/j.pop.2015.08.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center